Skip to content
OpenCapital
Get started

Regenxbio RGNX Other comprehensive income (loss)

Other comprehensive income (loss) at other companies

Opus Genetics logo
Opus GeneticsIRD
$0—
Biogen logo
BiogenBIIB
——
Arrowhead Research logo
Arrowhead ResearchARWR
——

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S6×+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTax.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's other comprehensive income (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's other comprehensive income (loss)?
Regenxbio (RGNX) reported other comprehensive income (loss) of -$183K in Q1 2026.
How has Regenxbio's other comprehensive income (loss) changed year-over-year?
Regenxbio's other comprehensive income (loss) decreased by 771.4% year-over-year, from -$21K to -$183K.
What is the long-term trend for Regenxbio's other comprehensive income (loss)?
Over 2 years (2021 to 2024), Regenxbio's other comprehensive income (loss) has grown at a 32.0% compound annual growth rate (CAGR), from -$2.21M to $3.85M.
What does other comprehensive income (loss) mean?
This represents the total of all items of comprehensive income that are excluded from net income, such as unrealized gains or losses on securities and foreign currency translation adjustments. It provides a broader view of the company's financial health by capturing changes in equity that do not stem from operational transactions. Monitoring this is essential for understanding the total change in shareholder value.